Portal de Periódicos da CAPES

Real-world resource use and costs of adjuvant treatment for stage III colon cancer

2013; Wiley; Volume: 24; Issue: 3 Linguagem: Inglês

10.1111/ecc.12154

1365-2354

C.W.M. van Gils, Saskia de Groot, Siok Swan Tan, Ken Redekop, Miriam Koopman, Cornelis J.A. Punt, C.A. Uyl-de Groot,

Health Systems, Economic Evaluations, Quality of Life

European Journal of Cancer CareVolume 24, Issue 3 p. 321-332 Original article Real-world resource use and costs of adjuvant treatment for stage III colon cancer C.W.M. van Gils MD, Corresponding Author C.W.M. van Gils MD Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamCorrespondence address: Chantal W.M. van Gils, Erasmus University Rotterdam, institute for Medical Technology Assessment, Burgemeester oudlaan 50, P.O. box 1738, Rotterdam 3000 DR, The Netherlands (e-mail: [email protected]).Search for more papers by this authorS. de Groot MSc, S. de Groot MSc Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorS.S. Tan PhD, S.S. Tan PhD Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorW.K. Redekop PhD, W.K. Redekop PhD Associate Professor Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorM. Koopman MD, PhD, M. Koopman MD, PhD Medical oncologist Department of Medical Oncology, University Medical Center Utrecht, UtrechtSearch for more papers by this authorC.J.A. Punt MD, PhD, C.J.A. Punt MD, PhD Professor/Medical Oncologist Department of Medical Oncology, Academic Medical Center, University of Amsterdam, AmsterdamSearch for more papers by this authorC.A. Uyl-de Groot PhD, C.A. Uyl-de Groot PhD Professor Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this author C.W.M. van Gils MD, Corresponding Author C.W.M. van Gils MD Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamCorrespondence address: Chantal W.M. van Gils, Erasmus University Rotterdam, institute for Medical Technology Assessment, Burgemeester oudlaan 50, P.O. box 1738, Rotterdam 3000 DR, The Netherlands (e-mail: [email protected]).Search for more papers by this authorS. de Groot MSc, S. de Groot MSc Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorS.S. Tan PhD, S.S. Tan PhD Researcher Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorW.K. Redekop PhD, W.K. Redekop PhD Associate Professor Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this authorM. Koopman MD, PhD, M. Koopman MD, PhD Medical oncologist Department of Medical Oncology, University Medical Center Utrecht, UtrechtSearch for more papers by this authorC.J.A. Punt MD, PhD, C.J.A. Punt MD, PhD Professor/Medical Oncologist Department of Medical Oncology, Academic Medical Center, University of Amsterdam, AmsterdamSearch for more papers by this authorC.A. Uyl-de Groot PhD, C.A. Uyl-de Groot PhD Professor Institute for Medical Technology Assessment, Erasmus University Rotterdam, RotterdamSearch for more papers by this author First published: 25 December 2013 https://doi.org/10.1111/ecc.12154Citations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Since the generalisability of trial-based economic evaluations may be limited, there is an increasing focus on real-world cost-effectiveness. Real-world studies involve evaluating the effects and costs of treatments in daily clinical practice. This study reports on the real-world resource use and costs of adjuvant treatments of stage III colon cancer in a population-based observational study. Analyses were based on a detailed retrospective medical chart review which was conducted for 206 patients with colon cancer treated in 2005 and 2006 in the Netherlands. Mean total costs per patient were €9681 for 5-FU/LV, €9736 for capecitabine, €32 793 for FOLFOX and €18 361 for CAPOX. Drug costs and the costs related to hospitalisations for chemotherapy administration were the main cost drivers. We identified a potential for substantial cost-savings when the 48 h administration of 5FU/LV in the FOLFOX regimen were to take place in an outpatient setting or be replaced by oral capecitabine as in the CAPOX regimen. This analysis based on detailed real-life data clearly indicates that clinical choices made in oncology based on efficacy of therapy have economic consequences. Considering today's reality of finite healthcare resources, these economic consequences deserve a formal role in clinical decision making, for instance in guideline development. References Aballea S., Boler A., Craig A. & Wasan H. (2007a) An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). European Journal of Cancer 43, 1687– 1693. Aballea S., Chancellor J.V., Raikou M., Drummond M.F. et al. (2007b) Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109, 1082– 1089. Aitini E., Rossi A., Morselli P., Vivorio B. et al. (2012) Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer. Cancer Management and Research 4, 99– 103. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M. et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England Journal of Medicine 350, 2343– 2351. Arkenau H.T., Arnold D., Cassidy J., Diaz-Rubio E. et al. (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26, 5910– 5917. Attard C.L., Maroun J.A., Alloul K., Grima D.T. et al. (2010) Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Current Oncology 17, 17– 24. Cassidy J., Douillard J.Y., Twelves C., McKendrick J.J. et al. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer 94, 1122– 1129. Cassidy J., Saltz L., Twelves C., Van Cutsem E. et al. (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 22, 2604– 2609. Centraal Bureau voor de Statistiek (2013) Consumer Price Index. Available at: http://www.cbs.nl. [accessed 30 June 2013]. Charlson M.E., Pompei P., Ales K.L. & MacKenzie C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40, 373– 383. Dane F., Akif Ozturk M., Gumus M., Guven A. et al. (2011) Efficacy, safety and prognostic features of resected colon carcinoma treated in ‘real world’ practice: a retrospective cohort-study. Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology 16, 257– 264. Di Costanzo F., Ravasio R., Sobrero A., Bertetto O. et al. (2008) Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer: economic evaluation in an Italian NHS setting. Clinical Drug Investigation 28, 645– 655. Douillard J.Y., Tilleul P., Ychou M., Dufour P. et al. (2007) Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 72, 248– 254. Eggington S., Tappenden P., Pandor A., Paisley S. et al. (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. British Journal of Cancer 95, 1195– 1212. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S. et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 49, 1374– 1403. Ferro S.A., Myer B.S., Wolff D.A., Poniewierski M.S. et al. (2008) Variation in the cost of medications for the treatment of colorectal cancer. The American Journal of Managed Care 14, 717– 725. Garrison L.P., Jr, Neumann P.J., Erickson P., Marshall D. et al. (2007) Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 10, 326– 335. van Gils C.W., Koopman M., Mol L., Redekop W.K. et al. (2012) Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncologica (Stockholm, Sweden) 51, 57– 64. van Gils C.W., de Groot S., Redekop W.K., Koopman M. et al. (2013) Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence. PharmacoEconomics. Haller D.G., Tabernero J., Maroun J., de Braud F. et al. (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29, 1465– 1471. Hsiao F.Y., Mullins C.D., Onukwugha E., Pandya N. et al. (2011) Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a ‘real world’ analysis using Surveillance, Epidemiology, and End Results-Medicare data. Journal of the American Geriatrics Society 59, 1717– 1723. Krol M., Koopman M., Uyl-de Groot C. & Punt C.J. (2007) A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opinion on Pharmacotherapy 8, 1313– 1328. Labianca R., Marsoni S., Pancera G., Torri V. et al. (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345, 939– 944. Lemmens V.E., van Halteren A.H., Janssen-Heijnen M.L., Vreugdenhil G. et al. (2005) Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 16, 767– 772. Lemmens V.E.P.P. & Coebergh J.W.W. 2006. Epidemiologie van colorectale tumoren. IKR Bulletin, 30. Ligtenberg G., Staal P.C., Goettsch W.G. & Knies S. (2013) Besluitvorming in de zorg op grond van kosteneffectiviteit: Consultatiedocument. 2013047960. Limat S., Bracco-Nolin C.H., Legat-Fagnoni C., Chaigneau L. et al. (2006) Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 7, 107– 113. Maniadakis N., Fragoulakis V., Pectasides D. & Fountzilas G. (2009) XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Current Medical Research and Opinion 25, 797– 805. Nederlandse Zorg autoriteit (The Dutch Healthcare Authority) (2009) Nza Tarieven. Available at: http://ctg.bit-ic.nl/Nzatarieven/top.do [accessed 30 June 2013]. Obrand D.I., & Gordon P.H. (1997) Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Diseases of the Colon and Rectum 40, 15– 24. Pandor A., Eggington S., Paisley S., Tappenden P. et al. (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 10, iii– iv, xi–xiv, 1–185. Pharmacotherapeutical Aid Committee (CFH) and Health Care Insurance Board (CVZ) (2009) Farmaco Therapeutisch Kompas. Available at: http://www.fk.cvz.nl [Accessed 2009]. Poos M.J.J.C., Smit J.M., Groen J., Kommer G.J. et al. (2005) RIVM Costs of Ilness in The Netherlands. Punt C.J. (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 15, 1453– 1459. Rothwell P.M. (2005) External validity of randomised controlled trials: ‘to whom do the results of this trial apply?’ Lancet 365, 82– 93. Shiroiwa T., Takeuchi T., Fukuda T., Shimozuma K. et al. (2012) Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 15, 255– 260. van Steenbergen L.N., Lemmens V.E., Rutten H.J., Wymenga A.N. et al. (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 23, 2805– 2811. Tan S.S., Hakkaart-van Roijen L., Al M.J., Bouwmans C.A. et al. (2008) A microcosting study of intensive care unit stay in the Netherlands. Journal of Intensive Care Medicine 23, 250– 257. Tan S.S., Van Gils C.W., Franken M.G., Hakkaart-van Roijen L. et al. (2010) The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 13, 712– 719. Twelves C., Wong A., Nowacki M.P., Abt M. et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. The New England Journal of Medicine 352, 2696– 2704. Twelves C., Gollins S., Grieve R. & Samuel L. (2006) A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 17, 239– 245. Twelves C., Scheithauer W., McKendrick J., Seitz J.F. et al. (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 23, 1190– 1197. Twelves C.J. (2006) Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clinical Colorectal Cancer 6, 278– 287. Ward S.E., Kaltenthaler E., Cowan J., Marples M. et al. (2006) The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. British Journal of Cancer 95, 27– 34. Woodward R.M., Menzin J. & Neumann P.J. (2013) Quality-adjusted life years in cancer: pros, cons, and alternatives. European Journal of Cancer Care 22, 12– 19. Xie Q., Wen F., Wei Y.Q., Deng H.X. et al. (2013) Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer. Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland 15, 958– 962. Citing Literature Volume24, Issue3May 2015Pages 321-332 ReferencesRelatedInformation